‘Pipeline In A Product’ Nipocalimab Starts Delivering For J&J
Moving Into Phase III For HDFN
Johnson & Johnson splashed a lot of cash to get hold of the FcRn inhibitor and is exploring nearly a dozen indications. Nipocalimab has advanced in one of those this week, severe hemolytic disease of the fetus and newborn.
